Pierre-François Pradat

Safety, Pharmacokinetic, and Functional Effects of the Nogo-A Monoclonal Antibody in Amyotrophic Lateral Sclerosis: A Randomized, First-In-Human Clinical Trial

Vincent Meininger, Pierre-François Pradat, Andrea M. Corse et al. · PLoS ONE · 2014 · 86 citations · Full text

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Vincent Meininger, Angela Genge, Leonard H van den Berg et al. · The Lancet Neurology · 2017 · 82 citations · Full text

Amyotrophic Lateral Sclerosis, Neurological Disorder, Clinical Neurology +4

Abnormalities of satellite cells function in amyotrophic lateral sclerosis

Pierre-François Pradat, Aude Barani, Julia Wanschitz et al. · Amyotrophic Lateral Sclerosis · 2011 · 80 citations

Identification of novel<i>FUS</i>mutations in sporadic cases of amyotrophic lateral sclerosis

Véronique Belzil, Hussein Daoud, Judith St‐Onge et al. · Amyotrophic Lateral Sclerosis · 2011 · 31 citations

Neurodegenerative Diseases, Fus Gene, Mendelian Disorder +15

Segmental somatosensory-evoked potentials as a diagnostic tool in chronic inflammatory demyelinating polyneuropathies, and other sensory neuropathies

R.M. Koutlidis, Xavier Ayrignac, Pierre-François Pradat et al. · Neurophysiologie Clinique · 2014 · 15 citations

Chronic Inflammatory, Neurophysiology, Neuroanatomy +13